Table 4.

Univariate and multivariate analysis of overall and progression-free survival.

Parameter	Overall survival				Progression-free survival
	Univariate p-value	Multivariate p-value	HR	95%-CI	Univariate p-value	Multivariate p-value	HR	95%-CI
uPA
Elevated vs. non-elevated	<0.001	0.015	2.074	1.15–3.74	<0.001	0.272	1.276	0.83–1.97
Menopausal status
Pre- vs. Postmenopausal	0.879	—	—	—	0.981	—	—	—
CTC counts
≥5 vs. <5 CTCs/7.5 ml blood	<0.001	<0.001	3.200	1.70–6.02	0.001	<0.001	2.193	1.43–3.36
Therapy line
>1st line vs. 1st line	<0.001	0.002	2.829	1.47–5.45	<0.001	<0.001	2.964	1.94–4.53
Grading
G3 vs. G1/2	0.183	0.042	1.351	1.01–1.81	0.390	0.167	1.151	0.94–1.41
ER status
Positive vs. Negative	0.215	0.189	0.671	0.37–1.22	0.209	0.020	0.602	0.39–0.92
PR status
Positive vs. Negative	0.527	—	—	—	0.171	—	—	—
HER2 status
Positive vs. Negative	0.231	0.128	0.634	0.35–1.14	0.973	0.929	0.982	0.66–1.46
Number of metastatic sites
Multiple vs. Single site	0.010	0.445	1.321	0.65–2.70	0.001	0.117	1.500	0.90–2.49
Metastatic spread
Visceral (+/− bone) vs. bone only	0.004	0.429	1.878	0.39–8.97	0.006	0.754	0.888	0.42–1.87
Serum HER2
Elevated vs. non-elevated	0.001	0.407	1.314	0.69–2.51	0.077	0.083	0.670	0.43–1.05
Serum RAS p2
1 ≥ 452 pg/ml vs. <452 pg/ml	0.002	0.033	2.181	1.06–4.48	0.009	0.145	1.516	0.87–2.65
Serum VEGF
≥367 pg/ml vs. <367 pg/ml	<0.001	0.390	1.284	0.73–2.27	<0.001	0.057	1.527	0.99–2.36
Serum EGFR
≥73 ng/ml vs. <73 ng/ml	0.007	0.072	0.497	0.23–1.07	0.270	0.422	0.838	0.54–1.29
Serum TIMP1
Elevated vs. non-elevated	<0.001	0.419	1.270	0.71–2.27	<0.001	0.500	1.167	0.75–1.83
Serum CAIX
Elevated vs. non-elevated	<0.001	0.214	1.433	0.81–2.53	<0.001	0.149	1.358	0.90–2.06